Get Your Co-Pay as Low as $0!*

* All patients with commercial insurance coverage are qualified for this program, which will cover 100% of their Xenazine co-payments. There's no paperwork required. Patients are not eligible for this program if their commercial insurance covers the entire cost of their prescription or if they have state or federal insurance coverage. Please carefully read the terms and conditions listed below.

See Real Stories

View true stories and see how Xenazine may make a difference with HD chorea symptoms.

Watch the videos

Frequently Asked Questions

Find answers to the most common Xenazine questions.

Read the FAQ
Home | Financial Help

REACH: Medication Assistance Program

Chorea Symptoms in Huntington's Disease

Dr. Sung discusses how chorea can affect Huntington's disease patients.

Learn about HD symptoms »

Craig and Sara's Huntington's Disease Story

Watch Craig and Sara discuss their experiences with chorea associated with Huntington's disease and how it can affect the entire family.

Hear from Craig and Sarah »

Matt’s HD Chorea

See how Matt and his caregiver and wife, Karen, worked to find treatment options, including Xenazine, to help manage his HD chorea.

Watch Matt’s Story »

Medication Assistance Program: REACH

Learn about Lundbeck’s medication assistance program, REACH, which offers financial assistance for Xenazine patients who qualify.

Discover what REACH might do for you »

REACH (which stands for Resources, Education and Access for patients with Chorea associated with Huntington’s disease) is a comprehensive assistance program designed to help patients who may benefit from Xenazine® (tetrabenazine) therapy manage their medication costs, if they qualify, and get their Xenazine prescriptions.

If you have questions concerning your ability to pay for your Xenazine prescription, you can call the Xenazine Information Center (XIC) at 1-888-882-6013. In some cases, the XIC will also call you if they need additional information related to your prescription.

There is help with medication assistance. We have some coverage, and Lundbeck also graciously helped us with some more coverage as they do with other eligible patients. If you would like more information about that, I encourage you to call the Xenazine Information Center."
~ Barbara, caregiver of person living with HD

Depending on your or your loved one's insurance coverage and financial need, there are a number of resources and programs that may assist you:

Xenazine Information Center (XIC)

A dedicated team is available to help patients, caregivers and physicians through the prescription process.

Co-Pay Assistance for Patients with Commercial
Insurance Plans

New and existing Xenazine patients who have commercial insurance coverage for Xenazine are qualified for this program, which will cover 100% of their Xenazine co-payments! There's no paperwork required. You are not eligible for this program if your commercial insurance covers the entire cost of your prescription or you have a state or federal coverage. Eligibility will be determined on a calendar year basis.

Co-Pay Assistance for Patients with State or Federal Insurance Plans

Patients with state or federal insurance coverage, such as Medicare, Medicaid, or TRICARE, may qualify for financial assistance with their co-payments from one or more charitable assistance programs.

Patients who do not qualify for any charitable co-pay assistance programs will receive Xenazine from Lundbeck free of charge; your insurance or health coverage will not be billed for the Xenazine provided.

Patient Starter Rx (prescription supply)**

Patients may receive their first Xenazine prescription within five days after the physician's office faxes in a completed prescription form.

*This offer is void where prohibited by law, taxed, or restricted. This offer may not be duplicated or transferred. This is not an insurance program. This offer may be changed or discontinued at any time without notice.
**Program not available in all states.

XENAZINE® (tetrabenazine) Tablets

Indications and Usage:

XENAZINE is a medicine that is used to treat the involuntary movements (chorea) of Huntington's disease. XENAZINE does not cure the cause of the involuntary movements, and it does not treat other symptoms of Huntington's disease, such as problems with thinking or emotions.

It is not known whether XENAZINE is safe and effective in children.

Important Safety Information:

  • XENAZINE can cause serious side effects, including:
    • depression
    • suicidal thoughts
    • suicidal actions
  • You should not start taking XENAZINE if you are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts.
  • Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts or feelings, or worsening depression. This is especially important when XENAZINE is started and when the dose is changed.
  • Do not take XENAZINE if you have liver problems or are taking monoamine oxidase inhibitors (MAOIs) or reserpine. Ask your doctor or pharmacist if you are not sure. At least 20 days should pass after stopping reserpine before starting XENAZINE.
  • Tell your doctor if you are pregnant or plan to become pregnant, breast-feeding, have breast cancer or a history of breast cancer, or have heart disease or an irregular heartbeat.
  • Tell your doctor about all the medicines you take. Do not start any new medicines while taking XENAZINE without talking to your doctor first.
  • Take XENAZINE exactly as prescribed by your doctor. The need for therapy should be evaluated on an ongoing basis with your doctor. The dose of XENAZINE should be adjusted slowly over several weeks for a dose that is appropriate for you. Tell your doctor if you stop taking XENAZINE for more than 5 days. Do not take another dose until you talk to your doctor. If your doctor thinks you need to take more than 50 mg of XENAZINE each day, you will need to have a blood test to see if a higher dose is right for you.
  • Neuroleptic Malignant Syndrome (NMS) is a potentially fatal side effect reported with XENAZINE. Call your doctor right away and go to the nearest emergency room if you develop these signs and symptoms that do not have another obvious cause: high fever, stiff muscles, problems thinking, very fast or uneven heartbeat, or increased sweating. XENAZINE should be stopped immediately if NMS is diagnosed.
  • XENAZINE can also cause other serious side effects, including: parkinsonism (slight shaking, body stiffness, trouble moving, or keeping your balance), restlessness (akathisia), trouble swallowing, irregular heartbeat, and dizziness due to blood pressure changes when you change position (orthostatic hypotension). Trouble swallowing may increase the risk of pneumonia. Uncontrolled movements called tardive dyskinesia (TD) may also develop in patients treated with XENAZINE. It is possible that the TD will not go away.
  • The risk of side effects, such as irregular heartbeat, parkinsonism, NMS, and restlessness (akathisia), may be increased when using XENAZINE with other drugs (e.g., dopamine antagonists or antipsychotics).
  • Sleepiness is a common side effect of XENAZINE; do not drive a car or operate dangerous machinery until you know how XENAZINE affects you. Alcohol and other drugs may increase sleepiness caused by XENAZINE.
  • Some side effects, such as depression, tiredness, trouble sleeping, sleepiness, parkinsonism, agitation, and restlessness (akathisia), may be dose-dependent. If the side effects don’t stop or lessen, your doctor should consider lowering the dose or stopping your XENAZINE. The most commonly reported side effects in studies with XENAZINE were sleepiness, trouble sleeping, depression, tiredness, anxiety, restlessness, agitation, and nausea.

For more information, please see the full Prescribing Information, including Boxed Warning, the Medication Guide or go to

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.


  1. "FDA Approves First Drug for Treatment of Chorea in Huntington's Disease", FDA News Release, August 15, 2008: Updated April 15, 2013. Accessed August 17, 2015.